FDA Panel Rejects Broad Olaparib Indication in Metastatic CRPC

(MedPage Today) -- In a near-unanimous vote on Friday, outside advisors to the FDA recommended a narrow indication should the agency approve olaparib (Lynparza) plus abiraterone (Zytiga) as initial treatment for metastatic castration-resistant...
Source: MedPage Today Public Health - Category: American Health Source Type: news